Gene · 970
Papers4,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,261 to 1,280 of 4,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Systematic transcriptome profiling of pyroptosis related signature for predicting prognosis and immune landscape in lower grade glioma. | BMC Cancer | 2022 | 35964070 | PubTator, text mining | PubMed |
| Soluble Immune Checkpoint Protein CD27 Is a Novel Prognostic Biomarker of Hepatocellular Carcinoma Development in Hepatitis C Virus-Sustained Virological Response Patients. | Am J Pathol | 2022 | 35963463 | PubTator, text mining | PubMed |
| The IFN-γ-related long non-coding RNA signature predicts prognosis and indicates immune microenvironment infiltration in uterine corpus endometrial carcinoma. | Front Oncol | 2022 | 35957871 | PubTator, text mining | PubMed |
| Activation Markers on B and T Cells and Immune Checkpoints in Autoimmune Rheumatic Diseases. | Int J Mol Sci | 2022 | 35955790 | PubTator, text mining | PubMed |
| Evaluation of a Patient With Non-Myoinvasive Uterine Serous Carcinoma Confined to a Polyp and Positive Peritoneal Washings With Somatic ARHGAP35 and KRAS Mutations. | Cureus | 2022 | 35949786 | PubTator, text mining | PubMed |
| Construction of a hypoxia-derived gene model to predict the prognosis and therapeutic response of head and neck squamous cell carcinoma. | Sci Rep | 2022 | 35945448 | PubTator, text mining | PubMed |
| Prognosis Analysis and Validation of Fatty Acid Metabolism-Related lncRNAs and Tumor Immune Microenvironment in Cervical Cancer. | J Immunol Res | 2022 | 35942212 | PubTator, text mining | PubMed |
| Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells. | Nat Biomed Eng | 2022 | 35941192 | PubTator, text mining | PubMed |
| Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. | J Immunother Cancer | 2022 | 35940825 | PubTator, text mining | PubMed |
| CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. | Front Immunol | 2022 | 35936003 | PubTator, text mining | PubMed |
| Epigenetic regulation and T-cell responses in endometriosis - something other than autoimmunity. | Front Immunol | 2022 | 35935991 | PubTator, text mining | PubMed |
| The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook. | Front Immunol | 2022 | 35935930 | PubTator, text mining | PubMed |
| CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy. | Adv Pharm Bull | 2022 | 35935042 | PubTator, text mining | PubMed |
| GNG12 as A Novel Molecular Marker for the Diagnosis and Treatment of Glioma. | Front Oncol | 2022 | 35928884 | PubTator, text mining | PubMed |
| Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases. | Front Immunol | 2022 | 35928814 | PubTator, text mining | PubMed |
| [Frequency, spectrum and risk factors of long COVID]. | Inn Med (Heidelb) | 2022 | 35925071 | PubTator, text mining | PubMed |
| Expression of CD70 Modulates Nitric Oxide and Redox Status in Endothelial Cells. | Arterioscler Thromb Vasc Biol | 2022 | 35924558 | PubTator, text mining | PubMed |
| Transcriptomic diversity in human medullary thymic epithelial cells. | Nat Commun | 2022 | 35918316 | PubTator, text mining | PubMed |
| Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities. | Front Immunol | 2022 | 35911706 | PubTator, text mining | PubMed |
| The Regulatory Effects of MicroRNAs on Tumor Immunity. | Biomed Res Int | 2022 | 35909469 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/papers?page=64